Overall Score

Scale Market Position

ARCT remains a small-cap biotech with a market cap of about $292M, limiting scale advantages and bargaining power.

Revenue per share is only $0.84 while price-to-sales is 12.28x, suggesting the market is still pricing in future pipeline success rather than current scale.

Profitability Cash Generation

TTM margins remain deeply negative, with operating margin at -4.33% and net margin at -3.92%, indicating no current operating moat.

Return on invested capital is -52.96% and free cash flow is negative, so the business is not yet converting its asset base into durable economic returns.

Cash on hand is strong relative to liabilities, but that liquidity does not offset the lack of earnings power.

Balance Sheet Resilience

The balance sheet is liquid, with a current ratio of 5.88x and cash ratio of 5.71x, which reduces near-term solvency risk.

Debt appears modest, with debt-to-equity at 0.13x and debt-to-assets at 0.10x, supporting financial flexibility.

However, negative operating cash flow and negative solvency metrics indicate the company still depends on capital markets or future clinical progress to sustain operations.

Moat Durability Intangibles

Gross margin is high at 83.19%, but that reflects biotech economics rather than a proven durable moat.

R&D intensity is very high at 3.62x revenue and SG&A is 1.86x revenue, showing the company is still in heavy development mode rather than harvesting a stable franchise.

No material intangible asset base is visible, and the current economics do not yet demonstrate durable pricing power or switching costs.